Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse

MLA

Viviane Gournay, et al. “Immune Landscape after Allo-HSCT: TIGIT- and CD161-Expressing CD4 T Cells Are Associated with Subsequent Leukemia Relapse.” Blood, vol. 140, Sept. 2022, pp. 1305–21. EBSCOhost, https://doi.org/10.1182/blood.2022015522.

APA

Viviane Gournay, Nicolas Vallet, Vivien Peux, Kristi Vera, Jennifer Bordenave, Marion Lambert, Aurélien Corneau, David Michonneau, Régis Peffault de Latour, Sophie Caillat-Zucman, Gérard Socié, & Mathieu F. Chevalier. (2022). Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood, 140, 1305–1321. https://doi.org/10.1182/blood.2022015522

Chicago

Viviane Gournay, Nicolas Vallet, Vivien Peux, Kristi Vera, Jennifer Bordenave, Marion Lambert, Aurélien Corneau, et al. 2022. “Immune Landscape after Allo-HSCT: TIGIT- and CD161-Expressing CD4 T Cells Are Associated with Subsequent Leukemia Relapse.” Blood 140 (September): 1305–21. doi:10.1182/blood.2022015522.